90 related articles for article (PubMed ID: 22774523)
1. [Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
Bershteĭn LM; Turkevich EA; Boiarkina MP
Vopr Onkol; 2012; 58(2):194-8. PubMed ID: 22774523
[TBL] [Abstract][Full Text] [Related]
2. [Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives].
Bershteĭn LM; Boriakina MP; Turkevich EA; Tsyrlina EV; Semiglazov VF
Vopr Onkol; 2010; 56(3):312-6. PubMed ID: 20804053
[TBL] [Abstract][Full Text] [Related]
3. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
5. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
6. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
7. Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.
Di GH; Lu JS; Song CG; Li HC; Shen ZZ; Shao ZM
J Exp Clin Cancer Res; 2005 Dec; 24(4):601-7. PubMed ID: 16471323
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological significance of aromatase expression in breast cancers].
Lu JS; Li HC; Cao DC; Di GH; Wu J; Shen KW; Shen ZZ; Shao ZM
Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1318-21. PubMed ID: 17217816
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S
Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974
[TBL] [Abstract][Full Text] [Related]
10. [Genetic testing of constitutive sensitivity to metformin in cancer patients with and without diabetes].
Bershteĭn LM; Vasil'ev DA; Ievleva AG; Imianitov EN
Vopr Onkol; 2013; 59(6):714-20. PubMed ID: 24624779
[TBL] [Abstract][Full Text] [Related]
11. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract][Full Text] [Related]
12. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.
Klubo-Gwiezdzinska J; Costello J; Patel A; Bauer A; Jensen K; Mete M; Burman KD; Wartofsky L; Vasko V
J Clin Endocrinol Metab; 2013 Aug; 98(8):3269-79. PubMed ID: 23709654
[TBL] [Abstract][Full Text] [Related]
13. Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.
Zhang Y; Kulp SK; Sugimoto Y; Farrar WB; Brueggemeier RW; Lin YC
Anticancer Res; 1998; 18(4A):2541-6. PubMed ID: 9703907
[TBL] [Abstract][Full Text] [Related]
14. Weight changes following the initiation of new anti-hyperglycaemic therapies.
Nichols GA; Gomez-Caminero A
Diabetes Obes Metab; 2007 Jan; 9(1):96-102. PubMed ID: 17199724
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
16. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
17. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Miki Y; Suzuki T; Tazawa C; Yamaguchi Y; Kitada K; Honma S; Moriya T; Hirakawa H; Evans DB; Hayashi S; Ohuchi N; Sasano H
Cancer Res; 2007 Apr; 67(8):3945-54. PubMed ID: 17440110
[TBL] [Abstract][Full Text] [Related]
18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
19. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
